NO178096C - Fremgangsmåte for fremstilling av et transdermalt leveringssystem for en farmasöytisk aktiv forbindelse - Google Patents

Fremgangsmåte for fremstilling av et transdermalt leveringssystem for en farmasöytisk aktiv forbindelse

Info

Publication number
NO178096C
NO178096C NO882559A NO882559A NO178096C NO 178096 C NO178096 C NO 178096C NO 882559 A NO882559 A NO 882559A NO 882559 A NO882559 A NO 882559A NO 178096 C NO178096 C NO 178096C
Authority
NO
Norway
Prior art keywords
transdermal delivery
preparation
delivery system
active compound
pharmaceutically active
Prior art date
Application number
NO882559A
Other languages
English (en)
Other versions
NO882559D0 (no
NO178096B (no
NO882559L (no
Inventor
John Michael Pawelchak
James Ronald Lawter
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of NO882559D0 publication Critical patent/NO882559D0/no
Publication of NO882559L publication Critical patent/NO882559L/no
Publication of NO178096B publication Critical patent/NO178096B/no
Publication of NO178096C publication Critical patent/NO178096C/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO882559A 1987-06-12 1988-06-10 Fremgangsmåte for fremstilling av et transdermalt leveringssystem for en farmasöytisk aktiv forbindelse NO178096C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6184287A 1987-06-12 1987-06-12

Publications (4)

Publication Number Publication Date
NO882559D0 NO882559D0 (no) 1988-06-10
NO882559L NO882559L (no) 1988-12-13
NO178096B NO178096B (no) 1995-10-16
NO178096C true NO178096C (no) 1996-01-24

Family

ID=22038497

Family Applications (1)

Application Number Title Priority Date Filing Date
NO882559A NO178096C (no) 1987-06-12 1988-06-10 Fremgangsmåte for fremstilling av et transdermalt leveringssystem for en farmasöytisk aktiv forbindelse

Country Status (16)

Country Link
EP (1) EP0294601B1 (no)
JP (1) JP2654092B2 (no)
KR (1) KR970000506B1 (no)
AT (1) ATE84714T1 (no)
AU (1) AU609142B2 (no)
CA (1) CA1305418C (no)
DE (1) DE3877630T2 (no)
DK (1) DK171746B1 (no)
ES (1) ES2043719T3 (no)
GR (1) GR3006938T3 (no)
IE (1) IE62735B1 (no)
IL (1) IL86334A (no)
NO (1) NO178096C (no)
NZ (1) NZ224891A (no)
PT (1) PT87704B (no)
ZA (1) ZA884186B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5045553A (en) * 1987-06-24 1991-09-03 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
US6075024A (en) 1991-11-27 2000-06-13 Sepracor Inc. Methods for treating infection using optically pure (S)-lomefloxacin
US5476854A (en) * 1991-11-27 1995-12-19 Sepracor Inc. Methods and compositions for treating bacterial infection using optically pure (R)-lomefloxacin
US5834496A (en) * 1991-12-02 1998-11-10 Sepracor, Inc. Methods for treating hypertension using optically pure S(-) felodipine
WO1994010986A1 (en) * 1992-11-09 1994-05-26 Pharmetrix Corporation Transdermal delivery of ketorolac
NZ530227A (en) * 2001-06-18 2006-09-29 Noven Pharma Enhanced drug delivery in transdermal systems
DK1628663T3 (da) 2003-05-15 2010-03-08 Roskamp Res Llc Fremgangsmåde til fremstilling af medikamenter til reduktion af amyloid-aflejring, amyloid-neurotoksicitet og mikrogliose
TWI500422B (zh) 2007-10-05 2015-09-21 Alzheimer S Inst Of America Inc 以（－）－尼代地平（ｎｉｌｖａｄｉｐｉｎｅ）對映異構物減低類澱粉沉積、類澱粉神經毒性及微神經膠細胞增生之方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284634A (en) * 1975-07-02 1981-08-18 Fujisawa Pharmaceutical Co., Ltd. 1,4-Dihydropyridine derivatives, and pharmaceutical method of the same
US4338322A (en) * 1975-07-02 1982-07-06 Fujisawa Pharmaceutical Co., Ltd. 1,4-Dihydropyridine derivatives, pharmaceutical compositions containing same and methods of effecting vasodilation using same
CA1117117A (en) * 1978-10-10 1982-01-26 Fujisawa Pharmaceutical Co., Ltd. 2-methyl-dihydropyridine compound, processes for preparation thereof and pharmaceutical composition comprising the same
JPS6016917A (ja) * 1983-07-08 1985-01-28 Yamanouchi Pharmaceut Co Ltd 塩酸ニカルジピンまたはニフエジピンの軟膏剤
JPS60258179A (ja) * 1984-06-04 1985-12-20 Yamanouchi Pharmaceut Co Ltd Ｙｍ−０９７３０のジアステレオマ−ａの右旋性光学異性体またはその酸付加塩，該化合物の製造方法および該化合物からなる医薬
DE3419128A1 (de) * 1984-05-23 1985-11-28 Bayer Ag, 5090 Leverkusen Dihydropyridinpraeparate und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
PT87704B (pt) 1993-03-31
EP0294601A3 (en) 1989-10-11
EP0294601A2 (en) 1988-12-14
NO882559D0 (no) 1988-06-10
ES2043719T3 (es) 1994-01-01
IL86334A (en) 1992-09-06
AU609142B2 (en) 1991-04-26
DK316788A (da) 1988-12-13
JP2654092B2 (ja) 1997-09-17
CA1305418C (en) 1992-07-21
KR890000090A (ko) 1989-03-11
IE62735B1 (en) 1995-02-22
EP0294601B1 (en) 1993-01-20
DE3877630D1 (de) 1993-03-04
DE3877630T2 (de) 1993-06-03
NZ224891A (en) 1992-06-25
JPS6413024A (en) 1989-01-17
GR3006938T3 (no) 1993-06-30
ATE84714T1 (de) 1993-02-15
DK316788D0 (da) 1988-06-10
NO178096B (no) 1995-10-16
PT87704A (pt) 1988-07-01
IE881749L (en) 1988-12-12
NO882559L (no) 1988-12-13
AU1761088A (en) 1988-12-15
KR970000506B1 (ko) 1997-01-13
DK171746B1 (da) 1997-05-05
ZA884186B (en) 1989-03-29

Similar Documents

Publication Publication Date Title
NO171787C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 8-azabicyclo(3.2.1)oct-2-en-forbindelser
FI920601A0 (fi) Tvaofasig anordning foer transdermal dosering av laekemedel.
ES2044087T3 (es) Un metodo para preparar una composicion de 13,14-dihidro-15-cetoprostaglandina estabilizada.
NO171853C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 7beta-(2-(tiazol-4-yl)-2-alkoksyiminoacetamido)-3-((1-pyrazolio)metyl)-3-cefem-4-karboksylat-forbindelser
NO165397C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tiazolforbindelser.
FI901096A0 (fi) Menetelmä farmakologisesti aktiivisten /3-(C16-C18)alkaanisulfinyyli- ja -sulfonyyli-2-metoksimetyylipropyyli/-(2-trimetyyliammonio-etyyli)fosfaattien valmistamiseksi
NO178096C (no) Fremgangsmåte for fremstilling av et transdermalt leveringssystem for en farmasöytisk aktiv forbindelse
NO169963C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive, substituerte 3,4-dihydro-2h-benzopyraner
DK376188A (da) Farmaceutisk dosisenhed
NO167734C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive substituerte aminderivater.
EP0328634A4 (en) Pharmaceutical compositions for the treatment of psoriasis
FI893163A (fi) Menetelmä 19-hydroksylaasi-inhibiittoreina käyttökelpoisten 19-substituoitujen progesteronijohdannaisten valmistamiseksi
IT1223343B (it) Formulazioni farmaceutiche per somministrazione transdermica
NO171211C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1,3-dioksaner
IL96506A0 (en) Transdermal system for administering pharmaceutical compounds under ph control
NO911237D0 (no) Fremgangsmaate for fremstilling av hydroxymethyl-indolizidiner og -kinolizidiner.
NO167381C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktiv (e)-2-(p-fluorfenethyl)-3-fluorallylamin.
AU575067B2 (en) Salts of l or (s)-3-(3,4-dihydroxyphenyl)-2- methylalanine esters
NO168586C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive diazepinon-forbindelser
NO912745L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1,2,5,6-tetrahydropyridinforbindelser.
NO912746D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive kinuklidinforbindelser.
NO172119C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive substituerte imidazol-forbindelser

Legal Events

Date Code Title Description
MK1K Patent expired